Philip James Wealth Mangement LLC Invests $475,000 in United Therapeutics Co. (NASDAQ:UTHR)

Philip James Wealth Mangement LLC acquired a new stake in United Therapeutics Co. (NASDAQ:UTHR) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 1,325 shares of the biotechnology company’s stock, valued at approximately $475,000.

Other hedge funds have also added to or reduced their stakes in the company. LSV Asset Management lifted its holdings in shares of United Therapeutics by 82.5% during the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after purchasing an additional 436,851 shares during the period. Swedbank AB acquired a new position in United Therapeutics during the 1st quarter worth about $97,316,000. Canada Pension Plan Investment Board grew its position in shares of United Therapeutics by 567.2% in the 1st quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock valued at $41,533,000 after buying an additional 153,700 shares during the last quarter. Pacer Advisors Inc. grew its position in shares of United Therapeutics by 19.6% in the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock valued at $178,972,000 after buying an additional 92,240 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of United Therapeutics by 49.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 276,531 shares of the biotechnology company’s stock valued at $88,089,000 after buying an additional 91,597 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently commented on UTHR shares. TD Cowen lifted their price objective on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. The Goldman Sachs Group upped their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. Oppenheimer lifted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Finally, Argus lifted their price objective on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $370.86.

United Therapeutics Stock Up 1.4 %

UTHR traded up $5.60 during trading on Friday, hitting $408.17. 28,373 shares of the company’s stock were exchanged, compared to its average volume of 462,641. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $410.79. The stock has a market cap of $18.22 billion, a P/E ratio of 17.68, a PEG ratio of 1.16 and a beta of 0.56. The business’s 50 day moving average is $358.27 and its two-hundred day moving average is $320.94.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The company had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm’s revenue was up 22.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.38 EPS. On average, sell-side analysts forecast that United Therapeutics Co. will post 25.1 earnings per share for the current year.

Insider Activity

In related news, Director Christopher Causey sold 510 shares of the stock in a transaction on Friday, November 1st. The stock was sold at an average price of $376.63, for a total value of $192,081.30. Following the completion of the sale, the director now directly owns 3,675 shares of the company’s stock, valued at approximately $1,384,115.25. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other United Therapeutics news, Director Christopher Causey sold 510 shares of the company’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $376.63, for a total value of $192,081.30. Following the completion of the sale, the director now directly owns 3,675 shares of the company’s stock, valued at approximately $1,384,115.25. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Michael Benkowitz sold 14,700 shares of the stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $374.46, for a total transaction of $5,504,562.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at approximately $964,983.42. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 81,422 shares of company stock worth $29,229,828 over the last 90 days. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.